To define critical parameters concerning interferon (IFN) 
consistently up-regulated in the presence of interferon (IFN). However, there is conflicting evidence regarding the NK cellactivating effects of clinically administered IFN. Many studies document significant IFN-induced increases in NK cell activity (5) (6) (7) (8) (9) (10) (11) , whereas others report absence of an IFN effect (9, 12) or occasional IFN-mediated depression of cytolytic activity (12, 13) .
Complexities of NK cell response regulation or kinetics in vivo may underlie these apparent discrepancies. For example, a single IFN injection may result in decreased NK cell activity several hours postinjection but lead to elevated levels of NK cell activity 24 -48 h later (5, 7) . On the other hand, NK cells may be initially activated, but become progressively less responsive to IFN after repeated daily injections over a course of several weeks (7, 8) . In addition, there exists in individuals a normal degree of variation over time in basal unstimulated levels of NK cell activity that must be taken into account when assessing immunomodulatory effects of an IFN regimen (11, 12, 14) . Although a substantial body of evidence exists that NK cells inhibit tumor growth in vivo in animals, evidence that they are involved in tumor immunity in humans is thus far indirect and somewhat less consistent (1, 2) . The use of biological response-modifying drugs such as IFN in controlled clinical trials under conditions in which NK cell responses are known to be optimally modulated may provide a means of clearly defining the importance of NK cells in control of human tumor growth. This study was, therefore, undertaken to define an IFN dose that would result in optimal NK cell activation. Cancer patients were given a series of sequential injections of different IFN dosages, the specific order of which was varied from one patient to the next according to a latin square experimental design. We assessed the effects of culturing mononuclear cells in vitro overnight before performance of NK cell assays with respect to variance in serial preinjection NK cell activity determinations and detectability of NK dose sequences were randomly assigned to patients. The designation of sequences was based upon a 6 X 6 latin square design (16) , such that each dose was preceded and followed by each of the other doses at least once (Table I) . In this manner, any specified dose was administered as the first injection in one patient, the second injection in another patient, the third injection in yet another patient, and so on. Thus, at each weekly injection during the first 6 wk of the study, six patients received six different doses. A seventh patient received the same sequence of injections as one of the others. In the 7th week of the study, each patient was given the same IFN dose received the previous week. Four patients received one additional injection of 106 U at a time point 3 wk or more after completion of the 7-wk study.
Detailed clinical findings in this study are to be published separately (Edwards, B. S., J. A. Merritt, R. C. Fuhlbrigge, and E. C. Borden, manuscript in preparation).
Cell preparations. As previously described (1 1 Chromium-release assay. Standard 5"Cr release assays were performed as previously described (20) in a total volume of 200 Mul/well using 96-well round bottom microplates (Linbro Chemical Co., Hamden, CT). Briefly, K562 target cells were labeled for 2 h at 370C with 100-200 MCi Na5tCrO4 (New England Nuclear, Boston, MA), washed twice, and 2 X 103 cells suspended in TCM were added to each well. Graded concentrations of PMC were added to wells in quadruplicate and incubated 6 h at 370C in 5% C02, after which supernatants were harvested, using a Titertek supernatant collection system (Flow Laboratories, Inc., Flow General Inc., McLean, VA), and counted in a gamma counter. Percent specific 5"Cr release mediated by NK (Table  II) . Therefore, no general trend toward diminished NK cell responsiveness to repeated weekly IFN injections occurred within the time period examined. A degree of variability existed in preinjection NK cell activity from one week to the next in a number of patients. To determine if this variability reflected carry-over effects from previous IFN injections, comparisons were made between levels of NK cell activity present just before injection of a specified dosage and 7 d later just before the next injection. Consistent with results of a similar analysis made in a separate study (23), no extended activating effects of single IFN injections at any of the tested dosages were detectable by this method of analysis (Table III) . Variability in preinjection NK cell activity may, therefore, have reflected normal day to day differences in basal cytolytic potential (1 1). It was noteworthy that weekly preinjection levels of NK cell activity varied to a remarkably small extent in two patients (A and G) in both of whom 3 X 106 U resulted in maximal boosting (Table II) (Table IV) . The mean decrease in variance of cytolytic activity, resulted from single intramuscular injecwas 52.5% (P = 0.024).
tions of 3 X 106 U of IFN. At a 10-fold greater dosage, When effects of IFN injections were assessed using freshly although boosting appeared to occur in some individuals prepared cells, results sharply contrasted with those obtained
(patients E and G in Table II) , the mean IFN effect over all in parallel experiments using overnight precultured cells. No patients was nil. A latin square dose sequencing schedule was mean augmenting effects of IFN treatment upon NK cell used to minimize the probability that differences in NK cell activity were detectable at any IFN doses (Table V) . Thus, activation could be attributed to experimental variables unreovernight culturing of mononuclear cells was of critical imlated to IFN dosage differences. Moreover, retrospective analysis portance in NK cell expression of IFN-mediated effects.
revealed no evidence for interinjection carry-over effects, the In vitro dose-response relationship. When incubated in putative existence of which stimulated our use of the latin vitro with mononuclear cells, the same IFN preparation used square dosing approach. NK cell activation measurable 24 h in treatment of patients resulted in NK cell activation that after injection of 3 X 106 U was no longer detectable 7 d approached a plateau of 300 U of IFN (Fig. 2) . A 10-fold postinjection (Table III) . No detectable "exhaustion" of NK greater IFN concentration, in excess of serum IFN concentracell responsiveness to IFN occurred in patients as a result of tions measured 8 h after injections of 3 X 106 U (range = 270-their receiving multiple weekly IFN injections over the 7-wk period encompassed by the study (Table II) Using mononuclear cells precultured overnight before assay in this and previous studies (1 1, 23) , enhancing effects upon NK cell cytolytic activity occurred which could only be attributed to prior exposure of NK cells to IFN in vivo. However, NK cell activation was undetectable when the period of cell culture intervening between cell separation and performance of cytotoxicity assays was omitted (Table V) . NK cells, exposed to IFN in vivo, may possibly fail to acquire or express an activated state until removed from the in vivo environment. An alternative explanation might be that cell separation procedures result in a degree of NK cell inactivation from which overnight culturing permits recovery. In accord with this interpretation were our findings that the increase in NK cell activity that resulted from overnight culture was accompanied by a significant reduction in interassay variance between serial weekly preinjection NK cell activity determinations (Table  IV) . Also favoring this interpretation were previous findings that Ficoll-Hypaque enhanced Fc receptor-dependent binding of serum IgG to cells during separation (24) and that such binding transiently inhibited NK cell activity (25). This effect of cell culture may account for some of the discrepancies in results of in vivo IFN treatment reported by other laboratories (12) .
The relationship between NK cell activation and antitumor response in humans remains to be determined. It may be relevant to our findings that Sherwin et al. (26) recently reported that 5 X 107 U doses of recombinant IFN-a given to breast cancer patients in a phase II clinical trial resulted in no significant antitumor effects. In contrast, in a previous multiinstitutional trial in which breast cancer patients were given 3 X 106 U doses of native Cantell IFN-a (Finnish National Red Cross), significant tumor responses occurred in 20% of the patients (8) . Although the IFN dose was only one parameter by which these two clinical trials differed, the difference in dosage should be considered as a potentially important factor. A clinical trial to examine the importance of IFN inmmunomodulatory effects should include use of lower IFN doses and would likely be most meaningful in patients with minimal tumor burdens. In such patients, immunomodulation may be of greatest potential efficacy.
